Cargando…

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?

Despite the constant improvement of therapeutical options, heart failure (HF) remains associated with high mortality and morbidity. While new developments in guideline-recommended therapies can prolong survival and postpone HF hospitalizations, impaired exercise capacity remains one of the most debi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voorrips, Suzanne N., Saucedo-Orozco, Huitzilihuitl, Sánchez-Aguilera, Pablo I., De Boer, Rudolf A., Van der Meer, Peter, Westenbrink, B. Daan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369142/ https://www.ncbi.nlm.nih.gov/pubmed/35955784 http://dx.doi.org/10.3390/ijms23158631

Ejemplares similares

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?
por: Nijholt, Kirsten T., et al.
Publicado: (2022)

The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients
por: van Woerden, Gijs, et al.
Publicado: (2022)

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
por: Gehlken, Carolin, et al.
Publicado: (2021)

Chronic Heart Failure and Exercise Intolerance: The Hemodynamic Paradox
por: Nilsson, Kent R, et al.
Publicado: (2008)

Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure
por: Kulej-Lyko, Katarzyna, et al.
Publicado: (2022)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Comorbidities complicating heart failure: changes over the last 15 years
por: Screever, Elles M., et al.
Publicado: (2022)

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
por: Yurista, Salva R., et al.
Publicado: (2020)

Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem
por: Upadhya, Bharathi, et al.
Publicado: (2015)

Short-Chain Fatty Acids in the Metabolism of Heart Failure – Rethinking the Fat Stigma
por: Palm, Constantin L., et al.
Publicado: (2022)

Impact of right ventricular contractile reserve during low‐load exercise on exercise intolerance in heart failure
por: Kinoshita, Masaki, et al.
Publicado: (2020)

Contributions of anemia to exercise intolerance in heart failure with preserved ejection fraction–An exercise stress echocardiographic study
por: Naito, Ayami, et al.
Publicado: (2023)

Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure
por: Van Tassell, Benjamin W., et al.
Publicado: (2012)

The fascial system and exercise intolerance in patients with chronic heart failure: hypothesis of osteopathic treatment
por: Bordoni, Bruno, et al.
Publicado: (2015)

Echocardiographic predictors of exercise intolerance in patients with heart failure with severely reduced ejection fraction
por: Zaborska, Beata, et al.
Publicado: (2018)

Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker
por: Bekfani, Tarek, et al.
Publicado: (2022)

Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Mitochondrial therapy for doxorubicin cardiomyopathy: nuclear factor-κB to the rescue?
por: Nijholt, Kirsten Theresa, et al.
Publicado: (2020)

Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction
por: Scandalis, Lina, et al.
Publicado: (2023)

Eicosanoid and eicosanoid-related inflammatory mediators and exercise intolerance in heart failure with preserved ejection fraction
por: Lau, Emily S., et al.
Publicado: (2023)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Association of beta‐hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort
por: Flores‐Guerrero, Jose L., et al.
Publicado: (2020)

Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients
por: McCoy, Jodi, et al.
Publicado: (2017)

Exercise intolerance and fatigue in chronic heart failure: is there a role for group III/IV afferent feedback?
por: Angius, Luca, et al.
Publicado: (2020)

Exercise intolerance in volume overload heart failure is associated with low carotid body mediated chemoreflex drive
por: Andrade, David C., et al.
Publicado: (2021)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

A Kinase Interacting Protein 1 regulates mitochondrial protein levels in energy metabolism and promotes mitochondrial turnover after exercise
por: Nijholt, Kirsten T., et al.
Publicado: (2023)

Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2018)

Red Cell Distribution Width as an Independent Predictor of Exercise Intolerance and Ventilatory Inefficiency in Patients with Chronic Heart Failure
por: Hong, Sung-Jin, et al.
Publicado: (2014)

Protein acetylation in skeletal muscle mitochondria is involved in impaired fatty acid oxidation and exercise intolerance in heart failure
por: Tsuda, Masaya, et al.
Publicado: (2018)

Pharmacoepigenetics in Heart Failure
por: Mateo Leach, Irene, et al.
Publicado: (2010)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

High selenium levels associate with reduced risk of mortality and new‐onset heart failure: data from PREVEND
por: Al‐Mubarak, Ali A., et al.
Publicado: (2022)

Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure
por: Vegter, Eline L., et al.
Publicado: (2017)

Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients
por: Shirakawa, Ryosuke, et al.
Publicado: (2019)

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
por: Withaar, Coenraad, et al.
Publicado: (2020)

Unraveling the Genotype‐Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity‐Related Cardiac Defects as a Major Disease Modifier
por: Nollet, Edgar E., et al.
Publicado: (2020)

Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure
por: Maffeis, Caterina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ef4ulqp28pj51nae09md0u6qqd